Cite
P2.07-005 Impact of Baseline Leptomeningeal and Brain Metastases on Immunotherapy Outcomes in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients
MLA
Henon, C., et al. “P2.07-005 Impact of Baseline Leptomeningeal and Brain Metastases on Immunotherapy Outcomes in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients.” Journal of Thoracic Oncology, vol. 12, no. 11, Number 11 Supplement 2, Nov. 2017, p. S2417. EBSCOhost, https://doi.org/10.1016/j.jtho.2017.11.064.
APA
Henon, C., Mezquita, L., Auclin, E., Ammari, S., Caramella, C., Le Pechoux, C., Botticella, A., Planchard, D., Gazzah, A., Ferrara, R., Lahmar, J., Martinez-Bernal, G., Adam, J., Soria, J., & Besse, B. (2017). P2.07-005 Impact of Baseline Leptomeningeal and Brain Metastases on Immunotherapy Outcomes in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients. Journal of Thoracic Oncology, 12(11, Number 11 Supplement 2), S2417. https://doi.org/10.1016/j.jtho.2017.11.064
Chicago
Henon, C., L. Mezquita, E. Auclin, S. Ammari, C. Caramella, C. Le Pechoux, A. Botticella, et al. 2017. “P2.07-005 Impact of Baseline Leptomeningeal and Brain Metastases on Immunotherapy Outcomes in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients.” Journal of Thoracic Oncology 12 (11, Number 11 Supplement 2): S2417. doi:10.1016/j.jtho.2017.11.064.